## Abstract Sunitinib (Sutent^®^, Pfizer) was approved in 2006 for the treatment of gastrointestinal and renal cancer. Isotope‐labelled derivatives have already been prepared for PET and ADME radiography. The preparation of ^13^C‐ and ^2^H‐labelled internal standards of sunitinib (SU11248) and its
A convenient synthesis of 13C4-Leflunomide and its primary metabolite 13C4-A77 1726
✍ Scribed by Robert J. Faragher; John. M. Motto; Maciej A. Kaminski; Adrian L. Schwan
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 113 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0022-2135
- DOI
- 10.1002/jlcr.701
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A convenient synthesis of leflunomide and its primary pharmacologically active metabolite A77 1726, each labeled with four ^13^C atoms has been achieved. Starting from ^13^C~4~‐ethyl acetoacetate, each step of the synthesis proceeds in 60–82% yield. Analysis of the mass spectra of the labeled and unlabeled materials demonstrates that the compounds prepared herein will be suitable as analytical standards for bioavailability studies. Copyright © 2003 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Phenyldithiane **3** is methylated with ^13^CH~3~I to give, through the thioacetal **4**, labelled acetophenone (**5**). NaOBr‐cleavage to the title compounds **1** and **2** (65 % and 76 %, respectively) and their use in the preparation of the dibromocyclopropane **6** and the dibromoo
## Abstract The synthesis of [4a‐^13^C]‐6‐methyltetrahydropterin, a synthetic cofactor for phenylalanine hydroxylase, is described. [2‐^13^C]‐ethyl bromoacetate was converted in four steps to [5‐^13^C]‐2,4‐diamino‐6‐hydroxypyrimidine in 86% yield. The latter was nitrosated, reduced, condensed with